Liposomes, a potential immunoadjuvant and carrier for a cryptococcal vaccine.
Mice immunized with a cryptococcal culture filtrate antigen (CneF) emulsified in complete Freund's adjuvant (CFA) develop an anticryptococcal cell-mediated immune response (CMI). CMI is detected by delayed-type hypersensitivity (DTH) reactions and by enhanced clearance of Cryptococcus neoformans from infected tissues. The objective of this research was to evaluate anticryptococcal DTH reactivity and clearance of cryptococci from groups of mice immunized with CneF encapsulated into liposomes (CneF-liposome) and compare the results to results from mice immunized with CneF-CFA. CBA/J mice were injected subcutaneously with vaccines or control formulations (saline-liposome or saline-CFA). Six days later the mice were footpad tested to assess their DTH response to CneF or the animals were challenged intravenously with 10(5) viable C. neoformans to determine clearance of infection. Clearance was evaluated 7 days later by enumeration of cryptococcal colony forming units (CFU) in lungs, spleens, livers, and brains of the infected mice. The CneF-liposome formulation induced a positive anticryptococcal DTH response and elicited increased clearance of C. neoformans from tissues as compared to mice treated with saline-liposome. Even though the CneF-liposome preparation did not induce as strong of a DTH response or as much protection as did CneF-CFA, our results indicate that liposomes are promising carriers for immunization with cryptococcal antigen and that such immunization can provide some protection to subsequent infection with C. neoformans.
Lambros
M P
MP
College of Pharmacy and Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA.
Schafer
F
F
Blackstock
R
R
Murphy
J W
JW
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000941:Antigens / Q000008:administration & dosage* / Q000276:immunology; D003453:Cryptococcosis / Q000517:prevention & control*; D003455:Cryptococcus neoformans / Q000276:immunology*; D004337:Drug Carriers; D005260:Female; D005657:Fungal Vaccines / Q000008:administration & dosage* / Q000276:immunology; D008081:Liposomes / Q000627:therapeutic use*; D051379:Mice; D008808:Mice, Inbred CBA
D000276:Adjuvants, Immunologic; D000941:Antigens; D004337:Drug Carriers; D005657:Fungal Vaccines; D008081:Liposomes